Skip to main content

IGC Pharma, Inc.

IGC
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001326205

No open-market purchases or sales by IGC Pharma, Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $1.41M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding IGC Pharma, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of IGC: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders25123−1
Shares2.56M703.8K2.80M+946.4K (+51.0%)
Value$1.11M$305.3K$1.19M+$388.7K (+48.3%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (3)

Institutions that held IGC Pharma, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to IGC in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.703,798$300.5K0.00%
Fullcircle Wealth LLC103,443$41.9K0.02%
Baader Bank INC10,533$3.17K0.00%

Sold out (4)

Institutions that held IGC Pharma, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of IGC in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Susquehanna International Group, LLP152,376$66.1K
Jane Street Group, LLC22,060$9.57K
FMR LLC36$15
Toronto Dominion Bank6$3

Not filed for Q3 2024 yet (1)

Institutions that held IGC Pharma, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding IGC in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.703,798$305.3K